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Bile acids are amphipathic molecules synthesized from cholesterol in the liver. Bile acid synthesis is a major pathway for
hepatic cholesterol catabolism. Bile acid synthesis generates bile ﬂow which is important for biliary secretion of free cholesterol,
endogenous metabolites, and xenobiotics. Bile acids are biological detergents that facilitate intestinal absorption of lipids and
fat-soluble vitamins. Recent studies suggest that bile acids are important metabolic regulators of lipid, glucose, and energy
homeostasis. Agonists of peroxisome proliferator-activated receptors (PPARα,P P A R γ,P P A R δ) regulate lipoprotein metabolism,
fatty acid oxidation, glucose homeostasis and inﬂammation, and therefore are used as anti-diabetic drugs for treatment of
dyslipidemia and insulin insistence. Recent studies have shown that activation of PPARα alters bile acid synthesis, conjugation,
and transport, and also cholesterol synthesis, absorption and reverse cholesterol transport. This review will focus on the roles of
PPARs in the regulation of pathways in bile acid and cholesterol homeostasis, and the therapeutic implications of using PPAR
agonists for the treatment of metabolic syndrome.
Copyright © 2009 T. Li and J. Y. L. Chiang. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Fibrates have been used for decades to treat hyper-
triglyceridemia or mixed hyperlipidemia for their abil-
ity to signiﬁcantly reduce plasma triglyceride levels [1].
Fibrate treatments also modestly elevate plasma HDL-C
and slightly decrease plasma LDL-C. Studies in the past
have revealed that the hypolipidemic eﬀects of ﬁbrates
are mainly a result of activation of the nuclear recep-
tor peroxisome proliferator-activated receptor α (PPARα),
which belongs to the nuclear hormone receptor superfamily
[2]. PPARα can be activated by natural fatty acids and
ﬁbrates. PPARα forms a heterodimer with nuclear receptor
RXR and recognizes a consensus PPAR responsive element
(PPRE) on its target gene promoters. PPARα regulates a
network of genes that promote lipolysis and fatty acid
β-oxidation, the major mechanisms mediating the lipid
lowering eﬀects of ﬁbrates. Based on the sequence homol-
ogy, two additional PPAR isoforms were identiﬁed and
named PPARγ and PPARβ/δ [3, 4]. PPARγ plays critical
roles in adipocyte diﬀerentiation, lipid storage, inﬂamma-
tion, and energy metabolism. PPARγ is activated by the
thiazolidinediones (TZDs) drugs, which improve insulin
sensitivity and lower plasma glucose levels in diabetes [1].
PPARδ plays a role in fatty acid and energy metabolism
in the muscle. Activation of PPARδ has been shown to
prevent dyslipidemia and obesity in animal models of
metabolic syndromes [5, 6]. PPAR agonists have been
extensively investigated for their therapeutic beneﬁts in
improving diabetes, dyslipidemia, and features of metabolic
syndromes.
Bile acids are amphipathic molecules derived from
cholesterol in the liver [7, 8]. Bile acid synthesis gener-
ates bile ﬂow from the liver to the intestine. The trans-
port of bile acids between liver and intestine is referred
to as the enterohepatic circulation of bile, which plays
important roles in liver function, liver physiology, and
metabolic regulation. Bile acids are detergent molecules
that facilitate biliary excretion of cholesterol, endogenous
metabolites and xenobiotics, and intestinal absorption of
lipids and nutrients. In cholestatic liver diseases, bile acids
accumulate at high concentrations in the liver, resulting
in hepatocyte injury, impaired liver function, ﬁbrosis and
cirrhosis. The liver plays a central role in maintaining
cholesterol homeostasis by balancing multiple pathways
including de novo cholesterol and bile acid synthesis, dietary2 PPAR Research
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Figure 1: Bile acid synthesis. Bile acids are synthesized from cholesterol in the liver through two pathways: the classic pathway and the
alternative pathway. In human liver, bile acid synthesis mainly produces two primary bile acids, cholic acid (CA), and chenodeoxycholic
acid (CDCA). Key regulatory enzymes in both pathways are indicated. CYP7A1 catalyzes the ﬁrst the rate-limiting step in the classic
pathway to convert cholesterol into 7α-hydroxycholesterol, while CYP27A1 initiates the alternative pathway by converting cholesterol into
27-hydroxycholesterol, which is then 7α-hydroxylated by oxysterol 7α-hydroxylase (CYP7B1). CYP8B1 regulates the cholic acid synthesis
in the classic pathway. In the intestine, primary bile acid CA and CDCA are dehydroxylated at the 7α-position by the bacterial enzymes to
produce the secondary bile acids, deoxycholic acid (DCA), and lithocholic acid (LCA), respectively.
cholesterol uptake, biliary cholesterol excretion, lipoprotein
synthesis, and reverse cholesterol transport. Defects in bile
acid synthesis due to mutations in bile acid biosynthetic
genes caused both abnormal cholesterol metabolism and
bile acid metabolism, which led to cholesterol gallstone
disease, dyslipidemia, and cardiovascular diseases in humans
[9]. This review will summarize the recent development
in understanding the role of PPARs in regulation of
bile acid and cholesterol homeostasis, and the therapeutic
implications in using PPAR agonists for treating metabolic
dyslipidemia and reducing the risk of cardiovascular and
heart diseases.
2. Bile Acid Synthesis andTransport
2.1. Bile Acid Synthesis. In humans, bile acid pool consists of
primary bile acids (cholic acid, CA, and chenodeoxycholic
acid, CDCA) and secondary bile acids (deoxycholic acid,
DCA, and lithocholic acid, LCA) [7]. Primary bile acids are
synthesized from cholesterol exclusively in the liver through
two general pathways, the classic pathway and the alternative
pathway(Figure 1)[9].Secondarybileacidsarederivedfrom
primary bile acids in the intestine by bacterial enzymes.
Enzymes that catalyze these multistep reactions are located
in the endoplasmic reticulum, mitochondria, cytosol, andPPAR Research 3
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Figure 2: Enterohepatic circulation of bile. Bile acids are transported across the canalicular membrane of hepatocytes by BSEP. Cholesterol
is either converted into bile acids for biliary secretion or transported by ABCG5/G8 into the bile. MDR3 mediates biliary phospolipids
secretion. Cholesterol, bile acids and phospholipids form mixed micelles to solublize cholesterol and reduce bile acid cytotoxicity. After
food intake, gallbladder contracts and releases bile acids into intestine. Approximately 95% of bile acids are reabsorbed into the enterocytes.
OSTα/OSTβ heterodimeric transporter mediates basolateral bile acid eﬄux into the portal circulation. NTCP and OATPs mediate hepatic
basolateral uptake of bile acids, which are then resecreted into the bile. In the hepatocytes, bile acid-activated FXR feedback inhibits
CYP7A1 and NTCP, and thus bile acid synthesis and uptake. Bile acid-activated feed-forward stimulates BSEP and biliary bile acid secretion.
Cholesterol derivatives oxysterols activate LXR, which induces ABCG5/G8 and biliary cholesterol secretion. In the intestine, FXR inhibits
ASBT and stimulates IBABP and OSTα and OSTβ.
peroxisomes. The classic pathway is also known as the
neutral pathway for most of its intermediates are neutral
sterols. In human, this pathway produces CA and CDCA
inapproximatelyequalamounts.Cholesterol7α-hydroxylase
(CYP7A1), a microsomal cytochrome p450 enzyme, cat-
alyzes the ﬁrst and rate-limiting step in the classic pathway to
convert cholesterol into 7α hydroxycholesterol [10]. Micro-
somal 3β-hydroxy-27-steroid dehydrogenase/isomerase (3β-
HSD) then converts 7α-hydroxycholesterol into 7α-hydroxy-
4-cholestene-3-one, which is the common precursor for
both CA and CDCA. 7α-hydroxy-4-cholestene-3-one can be
hydroxylated at C-12 position by microsomal sterol 12α-
hydroxylase (CYP8B1) and modiﬁed by other enzymes and
eventually converted to CA. Alternatively, without 12α-
hydroxylation, 7α-hydroxy-4-cholestene-3-one is converted
to CDCA. Mitochondrial sterol 27-hydroxylase (CYP27A1)
mediates the steroid side chain oxidation and cleavage
to give carboxyl groups in both CA and CDCA synthe-
sis [11]. The alternative pathway, also called the acidic
pathway, was originally revealed by the identiﬁcation of
several acidic intermediates which are not present in the
classic pathway [12, 13]. The alternative pathway mainly
produces CDCA. CYP27A1 catalyzes the ﬁrst two steps
and converts cholesterol into 27-hydroxycholesterol and
then 3β,7α-dihydroxy-5-cholestenoic acid [14]. Oxysterol
7α-hydroxylase (CYP7B1) then catalyzes the hydroxylation
reaction at C-7 position of these two intermediates, which
aresubsequentlyconvertedtoCDCAbythesameenzymesin
theclassicpathway.Inhumans,theclassicpathwayisthought
to be the major bile acid biosynthesis pathway in normal
physiology in humans.
2.2. Bile Acid Transport
2.2.1. Enterohepatic Circulation. Bile acids, once produced in
the liver, are transported across the canalicular membrane of
the hepatocytes into the bile and stored in the gallbladder.
After each meal, bile acids are released into the intestinal
tract, eﬃciently reabsorbed in the ileum, and transported
back to the liver via portal blood for reexcretion into the
bile.Thisprocessisreferredtoasenterohepaticcirculationof
the bile (Figure 2)[ 8]. Bile acid transporters play important
roles in this transport process [15]. The biliary excretion of
bile acids is the major driving force of bile ﬂow. The bile
acid pool size is deﬁned as the total amount of bile acids
circulating in the enterohepatic circulation. In humans, bile
acidpoolconsistsofCA,CDCA,andDCAinanapproximate
40 : 40 : 20 ratio, with a mass of around 2.5–3gm. After
reaching the small intestine, approximately 95% of the bile
acids are reabsorbed and only 5% is lost into the feces. The
daily loss of bile acids is compensated by de novo synthesis in
the liver and thus, a constant bile acid pool is maintained.4 PPAR Research
2.2.2. Hepatic Bile Acid Transport. Hepatocytes are polar-
ized epithelial cells with basolateral (sinusoidal) and apical
(canalicular) membrane domains. Hepatocytes take up bile
acids through the basolateral membrane, which is in direct
contact with the portal blood plasma, and excrete bile acid
at the canalicular membrane into the bile [16]. Bile acids are
conjugated with taurine or glycine in the peroxisomes and
present as bile salts. They cannot cross the cell membrane
and need active transport mechanisms for cellular uptake
[17]. Two bile acid transporters, Na+-dependent tauro-
cholate transporter (NTCP) and organic anion transporters
(OATPs) are responsible for basolateral bile acid transport
into the hepatocytes (Figure 2). The NTCP cotransports
two Na+ down its gradient into the hepatocytes along with
one molecule of conjugated bile acid [18]. Na+-dependent
bile salt uptake pathway accounts for 80% of the total
taurocholate uptake and is considered as the major bile acid
transport system located at the basolateral membrane [19].
The Na+-independent bile salt uptake is mediated by several
members of OATP family. These transporters have wide
substrate preference. Besides conjugated and unconjugated
bile acids, many amphipathic organic compounds such as
bilirubin, selected organic cations and numerous drugs are
also taken up by these transporters [20]. In rat liver, Oatp-
1, -2, and -4 account for the bulk Na+-independent bile acid
uptakewhileOATP-Cisthemostrelevantisoforminhumans
[21–24].
Since the biliary bile acids concentration is about 100
to 1000 fold higher in the bile than in the hepatocytes,
canalicular bile acid transport represent the rate-limiting
step in bile formation. Several members of the ATP-
binding cassette (ABC) transporter family are responsible
for transporting bile acids and other organic compounds
across the canalicular membrane against their concentration
gradients. The bile salt export pump (BSEP, ABCB11),
originally identiﬁed as the sister of P-glycoprotein (SPGP), is
mainly responsible for bile acid transport at the canalicular
membrane (Figure 2)[ 25]. Mutations in BSEP were ﬁrst
identiﬁed in patients with progressive familial intrahepatic
cholestasis subtype 2 (PFIC-2). The absence of functional
BSEP in the hepatic canalicular membrane and less than
1% of normal biliary bile acid concentration found in these
patientssuggestedthatBSEPisthemajorcanalicularbileacid
transport system [26].
After bile acids are pumped into the bile, they stimu-
late phospholipids and cholesterol secretions into the bile,
followed by passive inﬂow of water [27]. Phospholipids are
excreted via the phospholipid ﬂippase MDR3 (ABCB4), and
the major phospholipid in the bile is phosphatidylcholine
[28, 29]. Biliary free cholesterol secretion mediated by
ABCG5/G8 transporters is an important route for hepatic
cholesterol elimination. Mice lacking ABCG5 and ABCG8
showed decreased biliary cholesterol concentration, while
transgenicexpressionofABCG5andABCG8inmiceresulted
in increased biliary cholesterol secretion [30]. Bile acids,
phospholipids, and cholesterol are three major organic
solutes of the bile and once secreted, they form mixed
micelles to increase cholesterol solubility and reduce their
toxicity to the bile duct. Normal bile formation depends
largely on balanced secretion of these constituents. Impaired
secretions will disrupt the bile ﬂow and result in cholestasis
or cholesterol gallstone disease.
2.2.3. Intestine Bile Acid Transport. In the intestine lumen,
bile acids are reabsorbed mostly at the terminal ileum.
Like the hepatic basolateral uptake system, intestinal bile
acid uptake is also mainly mediated by the apical sodium-
dependentbilesalttransporter(ASBT)[31].Thistransporter
has substrate speciﬁcity for both primary and secondary
conjugatedandunconjugatedbileacids.Unlikesomehepatic
bile acid transporters that also mediate the secretion of
other organic compounds, the substrates for ASBT is strictly
limited to bile acids [32].
Once absorbed into the enterocytes, bile acids bind
the intestinal bile acid binding protein (I-BABP) and are
transported to the basolateral membrane for secretion
(Figure 2)[ 33]. Recently identiﬁed heterodimeric organic
solute transporters OSTα/OSTβ appeared to be the major
basolateral bile acid transport system in the intestine and
many other epithelial cells [34]. This is supported by studies
showing in mouse that overexpression of OSTα and OSTβ
enhanced basolateral eﬄux of taurocholate, while mice
lacking Ostα showed marked decreases in intestinal bile acid
absorption, serum bile acid concentration, and bile acid pool
size [35].
3. PPAR Regulation of Bile Acid Synthesis
andTransport
3.1. PPAR Regulation of Bile Acid Synthesis. Early clinical
studies have found consistent increases in biliary cholesterol
saturation and the risk of cholesterol gallstone formation in
hyperlipidemic human patients following long-term ﬁbrate
therapies [36–39]. Despite the observed decrease in plasma
LDL-C and increase in plasma HDL-C by ﬁbrate treatments,
biliary cholesterol secretion was found to be increased in
both normal and hyperlipidemic individuals after ﬁbrate
treatments. Biliary bile acid secretion was also reported to
be decreased by ﬁbrates [36, 38]. In contrast, biliary phos-
pholipid secretion, which may also aﬀect normal bile ﬂow
and cholesterol gallstone formation, seemed to be unaﬀected
[38, 39]. Fibrate treatment has been found to associate with
decreased CYP7A1 mRNA expression and enzyme activity.
In one study, bezaﬁbrate reduced hepatic CYP7A1 enzyme
activity by 60% in normolipidemic gallstone patients [40].
In another study, both gemﬁbrozil and bezaﬁbrate reduced
the rate of cholesterol 7α-hydroxylation by 55% in patients
with hypercholesterolemia [41]. Human with genetic defects
in CYP7A1 developed premature hypercholesterolemia and
gallstone disease [42]. It is likely that inhibition of hepatic
CYP7A1 activity following long-term ﬁbrate treatments may
account for the reduced cholesterol catabolism and bile
acid output, leading to imbalanced bile acid and cholesterol
secretion, increased biliary cholesterol saturation, and the
incidence of cholesterol gallstone formation.
Consistent with these observations, studies performed
in cell-based models or animal models revealed that ﬁbratePPAR Research 5
inhibition of hepatic CYP7A1 activity might be a result of
PPAR-dependent repression of Cyp7a1 transcription. Using
cell-based gene reporter assays, two groups showed that
PPARα/RXR and Wy14643 repressed both human and rat
CYP7A1 promoter reporter activities [43, 44]. Although a
putativePPREwasmappedinthehumanCYP7A1promoter,
this site did not bind PPARα/RXR, but was a previously
identiﬁedbindingsitefornuclearreceptorHNF4α,apositi v e
regulator of Cyp7a1 transcription. The mechanistic studies
further revealed that PPARα inhibited Cyp7a1 by decreasing
the cellular levels of HNF4α. Consistent with these in vitro
studies, ciproﬁbrate treatment was shown to inhibit CYP7A1
mRNAexpressionandenzymeactivityinbothratandmouse
liversinvivo[45].Althoughvariousfattyacidsmayactasthe
endogenous PPARα agonists, it seems that PPARα may not
play a critical role in controlling CYP7A1 gene expression
under normal physiology, as genetic knockout of Pparα in
mice did not aﬀect the basal Cyp7a1 transcription [44, 45].
However, the repressive eﬀect of ciproﬁbrate on CYP7A1
mRNA expression and enzyme activity was completely abol-
ished in mice lacking Pparα, providing an in vivo evidence
that ﬁbrates inhibition of Cyp7a1 was PPARα-dependent
[44, 45]. As mentioned earlier, CYP27A1 is the rate-limiting
enzyme in the alternative bile acid synthetic pathway, and
is also responsible for the side chain oxidation in the
classic bile acid synthetic pathway (Figure 1). The Cyp27a1
transcription was also repressed by ﬁbrate treatment in mice,
despite a much weaker reduction in the mRNA level and
enzyme activity when compared to those of CYP7A1 [45].
The ﬁbrate inhibition of CYP27A1 was also likely to be
PPARα-dependent, but the molecular mechanism of this
regulation is still not clear. Simultaneous inhibition of both
bile acid synthetic pathways may result in decreased hepatic
cholesterolcatabolismandoverallbileacidproductioninthe
liver. Unlike CYP7A1, which is speciﬁcally expressed in the
liver, CYP27A1 is also expressed in peripheral tissues such
as macrophages and intestines and is thought to play a role
in cellular cholesterol eﬄux by converting cholesterol into
oxysterols [46, 47]. It was found that CYP27A1 was upreg-
ulated by PPARγ activation in human macrophages [48, 49].
APPREwasidentiﬁedinthehumanCYP27A1promoterthat
speciﬁcally bound PPARγ/RXR heterodimer. Treatment of a
PPARγ agonist caused an increased cholesterol eﬄux from
human macrophages (Figure 3). Although how activation of
PPAR isoforms led to tissue speciﬁc regulation of CYP27A1
in the liver and macrophages is not clear, these ﬁndings are
in general consistent with the roles of PPARs in inhibition of
overall hepatic bile acid synthesis and stimulation of reverse
cholesterol transport (see Section 4.1).
The ratio of CA to CDCA in the bile determines the
hydrophobicity of the overall bile acid pool in humans,
and may aﬀect biliary cholesterol solubility in the bile.
Hydrophilic bile acid ursodeoxycholic acid has been used
clinically to dissolve cholesterol gallstones [50]. CYP8B1
regulates CA formation in the classic bile acid synthesis
pathway and plays an important role in controlling the
CA:CDCA ratio. Cloﬁbrate treatment has been shown
to increase CYP8B1 activity and mRNA level in rat liver
microsomes [51]. Treating mice a PPARα agonist Wy14643
resulted in an up regulation of CYP8B1 mRNA levels
and increased CA to CDCA/β-muricholic acid ratio, and
knockout of Pparα reversed that [52]. A functional PPRE
was identiﬁed in both mouse and rat CYP8B1 promoter,
suggesting a direct transcriptional activation of CYP8B1 by
PPARα.Bezaﬁbratetreatmenthasbeenshowntoincreasethe
CAtoCDCAratioinhumanpatients,whichfurthersuggests
that PPARα regulation of CYP8B1 may likely be conserved
in humans [40]. The observation that reduction in bile acid
output by gemﬁbrozil in human was mainly a result of
decreased CDCA in the biliary bile acid pool, while CA level
was not signiﬁcantly changed further suggested that PPARα
activation of CYP8B1 could compensate the reduction in
overallbileacidsynthesisandmaintainCAlevelsafterﬁbrate
treatment [38]. Since increased CA to CDCA ratio may favor
cholesterol solubilization, the direct induction of CYP8B1 by
PPARα may not contribute to the increased lithogenic index
of the bile by synthetic PPARα agonists.
3.2. PPAR Regulation of Bile Acid Transport. Limited studies
have implicated that PPARs may play a role in regulation of
bile acid conjugation and transport in the liver and intestine.
An early study showed that ciproﬁbrate feeding for two
weeks resulted in a signiﬁcant decrease of hepatic NTCP,
OATP1 and BSEP in mice, and these eﬀects were largely
abolished in Pparα null mice [53]. This was supported by
another study showing that down regulation of OATP and
NTCP by perﬂuorinated fatty acids were PPARα-dependent
[54]. Consistent with decreased expression of hepatic bile
acid transporters, biliary bile acid concentration was also
decreased by ciproﬁbrate [53]. Although this study did
not evaluate the biliary cholesterol saturation, the reported
increase in bile ﬂow and decreased biliary cholesterol
concentration following ciproﬁbrate treatment seemed to
contradict previous observations in humans. Further studies
are required to evaluate the role of PPARα in regulation
of the hepatic and biliary bile acid transport systems. In
the intestine, ASBT was found to be upregulated upon
PPARα activation by ciproﬁbrate in Caco2 cells [55]. The
intestinal bile acid binding protein (I-BABP) was also found
to be induced upon PPAR activation in Caco2 cells [56].
Upregulation of ASBT and I-BABP presumably increases
intestinal bile acid uptake and intracellular transport. How-
ever, it is unclear how PPARα may regulate intestinal
OSTα/OSTβ and basolateral eﬄux of bile acids. Mice lacking
functional OSTα/OSTβ heterodimer due to Ostα knockout
showed signiﬁcantly decreased bile acid pool and decreased
serum bile acid concentrations [35]. Changes in bile acid
concentration in hepatocytes and enterocytes may aﬀect
the activity of nuclear receptor FXR. FXR deﬁciency in the
liver has been implicated in the gallstone formation in mice
due to imbalanced expressions of cholesterol, bile acid, and
phospholipid transporters [57]. Decreased basolateral bile
acid eﬄux in Ostα null mice wasassociated with signiﬁcantly
decreased hepatic Cyp7a1 expression, likely due to induction
of intestinal ﬁbroblast growth factor 15 (FGF15), which
inhibits Cyp7a1 expression via bile acid activation of FXR
[35].6 PPAR Research
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Figure 3: Reverse cholesterol transport. In the intestine, dietary uptake of cholesterol is mediated by NPC1L1. ABCG5/G8 eﬄuxes sitosterols
and cholesterol back to the intestine lumen and limits intestinal sterol absorption. Oxysterols activate LXR, which induces ABCA1 and
ABCG1 to transport cholesterol to ApoA1 and HDL, respectively. PPARα activation reduces NPC1L1 and fractional cholesterol absorption,
and may promote cholesterol secretion by stimulating CYP27A1 and LXR activation of ABCA1 and ABCG1. In macrophages, LDLR and
CD36 mediate LDL and oxidized-LDL uptake, respectively. CYP27A1 converts cholesterol into 27-hydroxycholesterol, which may activate
LXR and cholesterol eﬄux via ABCA1 and ABCG1. Cholesterol can also be secreted in the form of 27-hydroxycholesterol. PPARγ induces
CYP27A1 and LXR, and positively regulates the cholesterol eﬄux from macrophages. PPARα induces ApoA1 and inhibits CETP, and thus
increases circulating HDL-C levels.
4. PPAR Regulation of Cholesterol Metabolism
Cholesterol is not only an essential cell membrane com-
ponent for maintaining normal cell functions but also the
precursor to all steroid hormones, bile acids, and oxysterols,
which are important regulators in diverse metabolic path-
ways. High intracellular cholesterol is toxic to the cells, and
high serum cholesterol built up in the arterial walls will lead
tothe plaqueformation, one of the initial steps in atheroscle-
rosis development. Hypercholesterolemia is considered as
one of the leading causes of many cardiovascular and heart
diseases and has become a major health concern worldwide.
Fibrates are used to treat dyslipidemia mainly for its ability
to stimulate fatty acid oxidation, while TZDs are used to
improve insulin sensitivity and glucose homeostasis. It is
suggested that PPARs may play a role in the development of
atherosclerosisbymodulatingcholesterolmetabolism aswell
as alleviating inﬂammation in the liver and vasculature [58].
The PPAR regulation of the pathways related to whole body
cholesterol homeostasis will be summarized below.
4.1.PPARandReverseCholesterolTransport. Plasmalipopro-
teinsaremacromoleculesthatcarrytriglycerides,cholesterol,
and other lipids for tissue distribution and metabolism. In
theblood circulation,cholesteroliscarried onLDLand HDL
particles. Studies in the past decades have linked elevated
plasma LDL-C to higher risks of cardiovascular incidence.
Thus, developing therapeutic agents that eﬃciently decrease
plasma LDL-C has been a major pharmacological eﬀort for
the prevention and treatment for coronary heart diseases.
So far, the use of HMG-CoA reductase inhibitor statins
has consistently shown adequate reduction of plasma LDL-
C levels by inhibiting the de novo cholesterol synthesis in
the liver and increasing LDL receptor-mediated clearance of
serum cholesterol [59–62]. However, even with an adequate
control of plasma LDL-C, only an approximate 20–35%
r e d u c t i o ni nm a j o rc a r d i o v a s c u l a re v e n t sw a ss e e ni nar a n -
domized clinical trial [63]. In fact, a signiﬁcant percentage
of patients had normal plasma LDL-C levels at the onset of
major cardiovascular events [64]. Early clinical trials have
found thatthe risk of cardiovasculardisease shows an inverse
correlation with plasma HDL-C levels, and low HDL-C has
been considered as a risk factor for cardiovascular diseases
[65, 66]. Compared to the eﬃcacy of statin therapies in
lowering plasma LDL-C, no therapies have been established
so far to raise plasma HDL-C, and current studies are in
search for therapeutic agents that raise plasma HDL-C levels
asameanstoachievefurtherriskreductionofcardiovascular
events in human patients.
The ability of plasma HDL in reducing the risk of
coronary heart disease resides in its physiological function
to transport excess cholesterol from peripheral tissues to
the liver for excretion or reutilization, a process that is
referred to as reverse cholesterol transport (Figure 3). The
roleofPPARαinregulatingHDLmetabolismandpromoting
reverse cholesterol transport is supported by the clinical
studies showing that ﬁbrate treatments not only led to a
marked reduction in plasma triglycerides but also caused
about 5–15% increase in plasma HDL-C levels, with a mod-
est reduction in LDL-C [67]. Accordingly, such induction
of HDL-C can be translated into an approximately 25%
reduction of the risk of coronary heart disease [68].
At the molecular level, ﬁbrate eﬀects on plasma HDL-
C level are thought to be at least in part mediated by
PPARα induction of the Apolipoprotein AI (ApoA-I). ApoA-
I and ApoA-II consist of the major protein moiety on HDLPPAR Research 7
particles and serve as the receptor ligands for hepatic HDL
uptake and metabolism [69]. HDL is initially synthesized
by the liver and intestine. ApoA-rich and lipid-poor pre-β-
HDL particles acquire cholesterol and phospholipids from
peripheral tissues and circulating VLDL and chylomicrons,
and then mature into HDL particles. Increased plasma
ApoA-I by ApoA-I infusion or transgenic expression of
ApoA-I were associated with increased plasma HDL-C and
decreased atherosclerosis in experimental animal models
[70–72]. PPARα activation by ﬁbrates induced ApoA-I
mRNA expression in human hepatocytes [73]. A PPRE has
been identiﬁed in the human ApoA-I promoter [74]. Inter-
estingly, PPARα eﬀect on ApoA-I seems to be species-speciﬁc
asPPREisnotconservedinrodentApoA1 genes[74].PPARα
activation in rodents actually decreased plasma HDL-C [73,
75], whereas genetic knockout of Pparα in mice showed
increased ApoA-I mRNA expression and plasma ApoA-I
and HDL levels [76]. Using human ApoA-I transgenic mice,
Bertouetal.demonstratedthatgemﬁbrozilincreasedhepatic
humanApoA-ImRNAexpressionandplasmahumanApoA-
I and HDL levels [73] ,w h i c hp r o v i d e da ni nv i v oe v i d e n c e
that PPARα activation positively regulates plasma HDL and
reverse cholesterol transport in humans.
The ATP-binding cassette transporter A1 (ABCA1) is
expressed in liver, intestine, and macrophages. ABCA1 plays
a central role in HDL formation by transporting intracellular
cholesterol to pre-β HDL particles (Figure 3). Both human
patients with nonfunctional ABCA1 due to autosomal
recessive disorder (Tangier disease) and ABCA1 knockout
miceshowedextremelylowplasmaHDLlevels,underscoring
the importance of ABCA1 in HDL metabolism [77, 78].
Several independent studies evaluating the PPAR eﬀect on
macrophage cholesterol eﬄux have found that both human
and mouse ABCA1 are induced upon PPARα and PPARγ
activation, suggesting PPAR may have an anti-atherogenic
function by regulating cholesterol eﬄux from macrophages
and thus reducing foam cell formation [79, 80]. However, no
PPRE has been identiﬁed in ABCA1, and PPAR induction
of ABCA1 expression may be an indirect eﬀect. ABCA1
is a direct target of the oxysterol receptor, liver orphan
receptor α (LXRα), which induces ABCA1 in response to
high cellular cholesterol activation [81]. LXRα expression is
induced by both PPARα and PPARγ agonists in human and
murine macrophages [82]. In Pparγ knockout mice, both
ABCA1 expression and cholesterol eﬄux were reduced in
macrophages [80]. PPRE has been identiﬁed in both human
and mouse LXRα promoter [82, 83]. Results from these
studies supported a PPARγ-LXRα-ABCA1 signaling cascade
that mediates cholesterol eﬄux in macrophages. However,
despite the critical role of cholesterol-laden macrophage in
foam cell formation and development of atherosclerosis, it is
believed that cholesterol eﬄux from macrophages may not
contribute signiﬁcantly to the total plasma HDL-C levels.
Instead, liver and intestine represent the major sources of
plasma HDL-C [84, 85]. PPARα activation by Wy14643
has been shown to induce Abca1 expression in the mouse
intestine [86]. However, as discussed in the next section, it
seems that PPARs exert a negative eﬀect on LXRα-dependent
gene transcription in the hepatocytes via physical interaction
with LXRα (next section). Thus, the relative contribution of
this PPAR cascade in overall plasma HDL metabolism need
to be further deﬁned.
PPARs may also regulate several genes that are involved
in HDL modiﬁcation and metabolism. An important step
in HDL metabolism is the cholesteryl ester transfer protein-
(CETP-)mediated transport of triglycerides from VLDL and
LDL to HDL in exchange for cholesterol esters. Mutations in
CETP has been shown to increase plasma HDL levels with a
modest reduction in LDL [87]. CETP is expressed in human
but not mice. A recent study of human CETP transgenic
mouse model showed that fenoﬁbrate signiﬁcantly reduced
plasma CETP activity, which was correlated with elevated
plasma HDL-C levels [88]. This study suggests that PPARα
activation may inhibit plasma CETP activity in humans
and may contribute to elevated HDL-C by ﬁbrate treat-
ment. However, the association between CETP inhibition
and cardiovascular risk reduction remains controversial, as
clinical trials showed that although inhibition of CETP
signiﬁcantly increased plasma HDL levels, further reduction
ofatheroscleroticprogressionwasnotseeninpatientsreceiv-
ing torcetrapib/atrovastatin combined therapy compared to
patients receiving atorvastatin alone [89, 90].
Given the potential role of ﬁbrates in raising plasma
HDL-C, the statin and ﬁbrate combined therapy has been
tested in several clinical trials. In these studies, addition of
ﬁbrate signiﬁcantly increased plasma HDL when compared
to statin alone [91–93]. Certain ﬁbrate/statin combination
therapies were well tolerated by the patients, while others
showed side eﬀects. Larger trials are needed to further
evaluate the beneﬁt and safety for using ﬁbrate and statin
combined therapies in the treatment of hyperlipidemia.
4.2. PPAR and Cholesterol Synthesis. To elucidate the mech-
anisms of cholesterol lowering eﬀect by ﬁbrates, a limited
number of studies have been carried out to investigate the
eﬀect of PPARs on hepatic de novo cholesterol synthesis.
It was shown that feeding wild-type mice a diet containing
the Wy14643 signiﬁcantly decreased hepatic cholesterol
synthesis rate, as measured by in vivo 3H2O incorporation.
Such reduction in cholesterol synthesis was not seen in
Pparα knockout mice [94]. Similar reduction of HMG-CoA
reductase activity and hepatic cholesterol synthesis was also
seen in rats receiving cloﬁbrate treatment [95]. Consistent
to these studies, PPARγ agonist troglitazone has been shown
to reduce cholesterol synthesis in hepatoma HepG2 cells and
intestine Caco2 cells [96].
Recently, a few studies have indicated that the PPAR
eﬀect on de novo cholesterol synthesis may be mediated
by PPAR-dependent inhibition of sterol response element
binding protein-2 (SREBP-2) protein cleavage and matu-
ration. SREBPs are transcriptional factors that regulate the
expression of genes in cholesterol, fatty acid and triglyc-
eride synthesis [97] .T h r e ei s o f o r m sh a v eb e e ni d e n t i ﬁ e d
in mammals, SREBP-1a, SREBP-1c and SREBP-2. While
SREBP-1 is believed to be mainly responsible for activation
of genes in fatty acid and triglyceride synthesis, SREBP-2
preferentially stimulates genes in cholesterol synthesis and8 PPAR Research
uptake, including HMG-CoA reductase and LDL receptor
(LDLR). SREBPs are synthesized as a 120 KDa precursor
protein that forms a complex with SREBP cleavage activating
protein (SCAP) and is localized in the ER membrane.
Upon sterol depletion, SREBP is translocated to the Glogi
apparatus where a two-step proteolytic cleavage process
releases a mature form of SREBP that enters the nucleus
and activates gene expression by binding to a consensus
SRE sequence in the gene promoters. The retention of
SREBP/SCAP complex in the ER depends on its binding
to the endoplasmic reticulum resident proteins, insulin-
induced gene-1 (Insig-1), and Insig-2. Insig-1 and insig-2
are highly expressed in the liver [98, 99]. Increased Insig-1,
but not Insig-2, was associated with increased endoplasmic
reticulum retention of SREBPs under high sterol conditions
[99].Kast-Woelbernetal.ﬁrstreportedthataPPARγ agonist
rosiglitazone induced Insig-1 expression in the adipose
tissue of diabetic db/db mice [100]. A functional PPRE was
identiﬁed in Insig-1 promoter and binds PPARγ. A similar
induction in Insig-1, but not Insig-2, mRNA expression
and a reduction of nuclear SREBP-2 by cloﬁbrate was also
reported in rats [101] .I nam o r er e c e n ts t u d y ,Q i ne ta l
showedthatPPARδ activationalsoinducedInsig-1inHepG2
cells [102], which correlated with a reduced amount of
SREBP-1 mature form. The study by Qin et al. also showed
that expression of PPARδ in db/db mice by adenovirus-
mediated gene transfer induced Insig-1 expression, inhibited
SREBP-1c maturation, and alleviated hepatic lipogenesis.
Although increased Insig-1 expression represses the cleavage
ofbothSREBP-1andSREBP-2,theseauthorsdidnotobserve
reduced expression of SREBP-2 target genes including LDLR
and HMG-CoA reductase, indicating PPARδ may preferen-
tially regulate SREBP-1c and hepatic fatty acid metabolism,
butnotcholesterolmetabolism.ItseemsthatthreePPARiso-
forms may regulate insig-1 expression. However, since three
PPAR isoforms exhibit diﬀerent tissue expression proﬁles,
activation of diﬀerent PPAR isoforms by pharmacological
agents may lead to somewhat distinct and tissue-speciﬁc
eﬀect on the activity of SREBPs, and thus fatty acid and
cholesterol metabolism.
4.3. PPAR and Intestinal Cholesterol Absorption. Intesti-
nal cholesterol absorption is thought to be coordinately
regulated by Niemann Pick C1-Like1 protein (NPC1L1)
and the ATP binding cassette half transporters ABCG5/G8
(Figure 3). NPC1L1 was ﬁrst identiﬁed as a candidate gene
for cholesterol transport based on its sequence homology to
NPC1 [103]. NPC1L1 is highly expressed in the mouse small
intestine. Genetic knockout of NPC1L1 in mice resulted in
markedly decreased fractional cholesterol absorption [104].
In addition, fractional cholesterol absorption in Npc1l1
knockout mice wasinsensitive tothe inhibition by ezetimibe,
a potent cholesterol absorption inhibitor, suggesting that
NPC1L1 plays a central role in intestinal cholesterol absorp-
tion. ABCG5 and ABCG8 are expressed on the canalicular
membrane of hepatocytes and the apical membrane of the
proximal small intestine. They form functional heterodimers
and transport dietary plant sterols and cholesterol into
the bile or intestine lumen. ABCG5/G8 were identiﬁed as
the defective genes in a rare genetic disorder called sitos-
terolemia,wherepatientsshowedmarkedlyincreasedplasma
and organ plant sterol levels due to increased intestinal
absorption and decreased biliary secretion [105]. Consistent
with the proposed function of ABCG5/G8 in cholesterol
transport, transgenic overexpression of ABCG5/G8 in mice
caused a signiﬁcant increase in biliary cholesterol secretion
and decreased intestinal fractional cholesterol absorption
[106].
Gemﬁbrozil or Wy14643 have been shown to inhibit
intestinal cholesterol absorption in rats and mice [86, 107].
Similarly, a potent PPARδ agonist GW610742 also reduces
intestinal cholesterol absorption, which is correlated with
decreased mRNA expression of NPC1L1 in the mouse
intestine[108].Recently,Valaseketal.showedthatlong-term
fenoﬁbrate administration inhibits NPC1L1 mRNA expres-
sion and fractional cholesterol absorption. These eﬀects were
abolished in Pparα knockout mice and further conﬁrmed
the role of PPAR in intestinal cholesterol absorption [109].
The molecular mechanism of PPAR inhibition of NPC1L1 is
not clear, and is likely to be an indirect eﬀect, secondary to
changes caused by PPAR activation [109].
The mechanism of PPARs regulation of ABCG5/G8 is
not known. Valasek reported that intestinal ABCG5 and
ABCG8 are not involved in reduced cholesterol absorption
in fenoﬁbrate-fed mice [109]. In contrast, PPARα was impli-
cated in the fasting-induced hepatic ABCG5/G8 expression
in mice [110].
5. Crosstalkof PPAR withOther
Nuclear Receptors in Cholesterol and
Bile AcidMetabolism
5.1. PPAR Crosstalk with LXR. The LXR subfamily of
nuclear receptor consists of two isoforms: LXRα and LXRβ.
LXRα is expressed at high levels in liver, intestine and
macrophages, while LXRβ is universally expressed in most
tissues. LXRα is activated by oxysterols such as 22(S)-
hydroxycholesterol, 24(S), 25-epoxycholesterol, and 27-
hydroxycholesterol, whose levels are thought to be propor-
tional to cellular cholesterol levels [111, 112]. Extensive stud-
ies in the past have established LXRα as a central regulator
of tissue cholesterol homeostasis by regulating a network of
genes in cholesterol metabolism and excretion. In rodent,
but not human livers, LXRα stimulates conversion of excess
cholesterol to bile acids by activation of hepatic Cyp7a1
expression [113]. LXRα also stimulates the cholesterol eﬄux
transporters ABCG5/G8 for biliary free cholesterol secretion
[114]. In the intestine and liver, LXRα induces ABCA1 and
ABCG1, which transport cholesterol to ApoA-I and HDL
and thus promote reverse cholesterol transport [81, 115].
In macrophages, LXRα-dependent activation of ABCA1 and
ABCG1 prevents cholesterol accumulation and atheroscle-
rosis progression. Mice lacking LXRα are susceptible to
high cholesterol diet induced hypercholesterolemia, while
activation of LXRα by synthetic agonists show protective
eﬀects in hypercholesterolemic mice, demonstrating thePPAR Research 9
critical role of LXRα in maintaining whole body choles-
terol homeostasis [116–118]. However, the development of
potent LXRα agonist for treating hypercholesterolemia was
hindered due to the lipogenic eﬀect of LXRα activation [119,
120]. Mice receiving LXRα agonists showed signiﬁcantly
increased hepatic fatty acid synthesis and elevated plasma
triglyceride levels. It is now clear that the lipogenic eﬀect
of LXRα is mainly due to its transcriptional activation of
SREBP-1c [121, 122].
PPARα was identiﬁed as an interacting partner of LXRα
in a yeast-two hybrid assay [123]. It has been shown
that LXRα interaction with PPARα blocked PPARα/RXR
heterodimer binding to the PPRE and resulted in inhibit-
ing PPARα target genes. Another study showed that
PPARα/LXRα interaction was enhanced by addition of an
LXRα agonist TO901317, and PPARα/LXRα interaction
reducedPPARα/RXRαheterodimerformation[124].Inmice
fed TO901317, PPARα-regulated genes in hepatic fatty acid
oxidation were repressed suggesting that activation of LXRα
may repress hepatic fatty acid oxidation via inhibition of
PPARα transcriptional activity. In contrast, LXRα activation
induces PPARα in mouse intestine [125, 126]. Further more,
activation of LXRα by a speciﬁc agonist induced not only
LXRα target genes but also PPARα target genes in mouse
intestine. As discussed in the previous section, PPARα is also
implicated in the intestinal cholesterol absorption and trans-
port process. Thus, the identiﬁcation of intestine-speciﬁc
LXRα-PPARα signaling cascade may provide an additional
pathway for LXRα/PPARα in coordinated regulation of
cholesterol metabolism in the intestine.
The eﬀect of PPARs on LXRα-dependent transcriptional
network has also been studied, and both positive and nega-
tive eﬀects have been reported. Polyunsaturated fatty acids
(PUFA) inhibit hepatic lipogenesis by decreasing SREBP-
1c mRNA and protein in cultured hepatocytes and animal
livers [127, 128]. A study by Yoshikawa et al. suggested that
activation of PPARα caused decreased LXRα/RXR binding
to the SREBP-1c gene promoter and resulted in down
regulation of SREBP-1c and lipogenic gene expression [121,
129]. The ﬁnding that PPARα activation inhibits SREBP-
1c is in agreement with the known function of PPARα in
stimulatinghepaticfattyacidoxidation anditslipidlowering
eﬀect in humans. Consistent with this notion, Matsusue
et al. reported that activation of PPARδ downregulated
angiopoietin-like protein 3 gene in lipid metabolism via
an LXRE on the angiopoietin-like protein 3 gene pro-
moter [130]. However, these ﬁndings seem to contradict
the existing reports that activation of both PPARα and
PPARγ in macrophages induces LXRα gene expression and
LXRα-dependent cholesterol eﬄux [79, 80, 130]. Because
functional PPRE has been identiﬁed in both human and
mouse LXRα gene promoter, the lack of activation of LXRα
by PPARs in the liver is still not fully understood [82,
83]. In general, ﬁbrate therapy showed protective eﬀect
against atherosclerosis in men. However, studies with ﬁbrate
administration in mice yielded mixed results. In hyper-
lipidemic LDLR knockout mice, activation of PPARα or
PPARγ have been shown to prevent atherosclerosis and foam
cell formation, and such protective eﬀect seems to involve
ABC-dependent cholesterol eﬄux pathways [131]. Similar
antiatherogenic eﬀects of PPARs were also found by studies
using ApoE knockout mice [132, 133]. In contrast, genetic
deletion of PPARα in ApoE knockout mice resulted in more
severe atherosclerosis [134]. Another study reported that
ciproﬁbrate treatment in ApoE knockout mice promoted the
progression of atherosclerosis [135].
5.2. PPAR Crosstalk with FXR. It is reported that bile
acids, acting through nuclear receptor FXR, induced human
PPARα gene in HepG2 cells [136]. It is known that activation
of FXR by bile acids or a synthesis FXR agonist negatively
regulates hepatic fatty acid synthesis and plasma triglyceride
levels [137]. The lipid lowering eﬀects of bile acids are
thought to be attributable to the inhibition of SREBP-1c
activity in the liver. In concert, FXR induction of PPARα
may be an additional mechanism to antagonize hepatic
SREBP-1c activity and promote hepatic fatty acid oxidation.
However, the FXRE on the human PPARα is not conserved
in murine Pparα gene promoter [136]. Consistent with
this ﬁnding, mice fed a diet supplemented with bile acids
antagonized PPARα agonist eﬀect [138]. It seemed that bile
acid-activated FXR/SHP pathway was not involved in such
regulation as bile acids still inhibited PPARα activity in Fxr
knockout mice [138]. Bile acid-activated cellular signaling
pathways may be implicated in the negative regulation of
PPARα in mice. SHP is generally considered as a negative
regulator by interacting with other nuclear receptors and
transcriptional factors. Both PPARα and PPARγ physically
interact with SHP [139, 140]. Surprisingly, both studies
found that SHP was able to enhance PPARα-a n dP P A R γ-
mediated transcriptional activity. The study by Nishizawa
et al. showed that SHP competed with corepressrors for the
binding to PPARγ, which provided a possible explanation of
SHP eﬀect on the transcriptional activity of PPARs [140]. As
SHP does not possess intrinsic transcriptional activity, the
positive eﬀect of SHP on PPAR transcriptional activity was
somehow unexpected, and the physiological relevance of the
role of SHP in regulating PPAR signaling needs to be further
deﬁned in future studies.
6. Conclusion andFuturePerspectives
In the past decades, the roles of PPARs have been
extended from stimulating fatty acid oxidation and glu-
cose metabolism to regulating cholesterol and lipoprotein
metabolism, bile acid metabolism, energy homeostasis and
inﬂammation,andsoforth.Currently,mostoftheregulatory
roles of PPARs turned out to be beneﬁcial in improving
dyslipidemia and glucose homeostasis and reducing the
risks of major cardiovascular and heart events, while others
may represent adverse eﬀects associated with the use of
certain PPAR agonists. With the ability of PPARs to crosstalk
with other protein factors and cellular signaling pathways,
it is not surprising that more regulatory roles of PPARs
have been revealed. Long-term ﬁbrate therapy represses
hepatic bile acid synthesis and increases the incidence of
cholesterol gallstone. However, the role of PPAR in bile acid10 PPAR Research
transport are still not clear. The use of PPAR agonists for
treating steatohepatitis has also been considered due to their
known eﬀects in fatty acid metabolism, inﬂammation, and
hepaticﬁbrosis[141–145].Inadditiontotherepressiveeﬀect
on hepatic bile acid synthesis, PPARα have recently been
implicated in the positive regulation of bile acid conjugation
and toxicity [146–149]. Whether these regulatory roles of
PPARα represent any beneﬁcial eﬀects in cholestatic liver
injury needs to be further explored. PPAR agonists have
been proven to be a group of drugs with great therapeutic
potentials in treating metabolic syndromes. Clinical trials
are being conducted to evaluate the eﬃciency and safety
of ﬁbrate/statin combined therapy. Given the increasingly
recognized epidemic of obesity, diabetes, and chronic liver
diseases associated with metabolic disorders, more potent
and selective PPAR agonists need to be developed to achieve
desirable biological eﬀects and to avoid adverse eﬀects. The
development of such agents will depend on a better under-
standingoftheregulatoryrolesofPPARsindiversebiological
processes beyond triglyceride and glucose metabolism.
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